CAS 649735-46-6 appears in our catalog under these names: Brivanib/ 98.87% (existing batch purity), Brivanib (BMS–540215), BMS-540215, Brivanib 96%, Brivanib, 96%, 96%. Offered by: TargetMol, GLPBio, Chemat, Ambeed, MedChemExpress. Available pack sizes: 1mg, 2mg, 5mg, 10mg, 25mg, 50mg, 100mg, 10mM (in 1ml dmso).
Brivanib is a secondary alcohol resulting from the hydrolysis of the carboxylic ester group of brivanib alaninate. It is a dual VEGFR-2/FGFR-1 kinase inhibitor whose alanine prodrug, brivanib alaninate is currently under development as an oral agent for the treatment of cancer. It has a role as an antineoplastic agent, an angiogenesis inhibitor, a drug metabolite, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a fibroblast growth factor receptor antagonist and an apoptosis inducer. It is a fluoroindole, an aromatic ether, a secondary alcohol, a diether and a pyrrolotriazine.
Source: ChEBI
| Molecular formula | C19H19FN4O3 |
|---|---|
| Molecular weight | 370.4 g/mol |
| IUPAC name | (2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol |
| InChIKey | WCWUXEGQKLTGDX-LLVKDONJSA-N |
| SMILES | CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C |
Computed by PubChem (NCBI)